Akihiko Osaki

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3–Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3–Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial

Ian E. Krop, Norikazu Masuda, Toru Mukohara et al. · Journal of Clinical Oncology · 2023 · 122 citations · Full text

Medicine, Oncology, Pharmacology +15

Bevacizumab Induces Acute Hypoxia and Cancer Progression in Patients with Refractory Breast Cancer: Multimodal Functional Imaging and Multiplex Cytokine Analysis

Shigeto Ueda, Toshiaki Saeki, Akihiko Osaki et al. · Clinical Cancer Research · 2017 · 111 citations · Full text

Medicine, Nuclear Medicine, Pharmacology +17

In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab

Shigeto Ueda, Toshiaki Saeki, Hideki Takeuchi et al. · British Journal of Cancer · 2016 · 102 citations · Full text

Medicine, Oncology, Pharmacology +17

Epidermal growth factor receptor expression as a prognostic indicator in breast cancer

Masakazu Toi, Akihiko Osaki, Hirofumi Yamada et al. · European Journal of Cancer and Clinical Oncology · 1991 · 97 citations

Medicine, Cancer Biology, Oncology +14